Shaanxi Pharmaceutical Group currently has 32 enterprises and institutions, including 1 public institution, 19 joint-stock companies, 5 wholly-owned companies, and 7 holding companies. Since the reform and opening up, foreign capital has been introduced and Sino-foreign joint ventures such as "Xi'an Janssen", "Xi'an Zhengda", "Xi'an Global" and "Xi'an Debao" have been successfully established. Covering the fields of pharmaceutical industry, pharmaceutical commerce, pharmaceutical scientific research, Chinese herbal medicine cultivation, pharmaceutical packaging and other fields, it has become a large state-owned pharmaceutical enterprise focusing on investment and integrating science, industry and trade. As of the end of June 2009, total assets were 4.4 billion yuan and net assets were 1.8 billion yuan.
Currently, Shaanxi Pharmaceutical Group has 362 drug production varieties and 429 drug approval numbers, including 171 western medicines, 1 biological product, 250 traditional Chinese medicines, and 8 others. Involving 16 dosage forms including API tablets, capsules, injections, suppositories, and oral liquids. There are 11 famous trademarks, 16 famous brand products, 11 protected varieties of traditional Chinese medicine, 122 registered trademarks, and 21 patented products. There are 2 products with annual sales revenue exceeding 500 million yuan and 6 products exceeding 100 million yuan. The sales network covers the country and the products are exported to more than ten countries and regions in Asia, Europe, America and so on.